← Back to all trials
Not Yet Recruiting
NCT05688020
Tranexamic Acid During Upper GI Endoscopic Resection Procedures
Conditions: Gastric Polyp, Gastric Neoplasm, Duodenal Neoplasms, Esophageal Neoplasms
Sex: All
Ages: 18 Years – N/A
Phase: PHASE4
Enrollment: 200
Sponsor: Assaf-Harofeh Medical Center
Location: Israel
Summary
Endoscopic resection of gastrointestinal lesions may prevent cancer.
However, resection is associated with adverse events such as bleeding.
Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding.
The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of upper gastrointestinal lesions.
Eligibility Criteria
Inclusion Criteria:Patients referred for endoscopic resection of a non-neoplastic and neoplastic lesions in the upper GI presenting to our tertiary academic center.Age > 18 yearsExclusion Criteria:patients with histories of allergic reactions to TXAhistory of seizurespregnancy
Source: ClinicalTrials.gov (NCT05688020). StuddyBuddy aggregates publicly available trial information.
